The aim of this study was to prove the feasibility of continuous subcutaneous glucose monitoring in humans using the comparative microdialysis technique (CMT). The performance of the CMT was determined by comparing tissue glucose values with venous or capillary blood glucose values in healthy volunteers and type 1 diabetic subjects. The CMT is a microdialysis-based system for continuous online glucose monitoring in humans. This technique does not require calibration by the patient. Physiological saline with glucose (5.5 mM) is pumped in a stop-flow mode through a microdialysis probe inserted into the abdominal s.c. tissue. Tissue glucose concentration is calculated by comparing the dialysate and perfusate glucose concentrations. The time delay due to the measurement process is 9 min. We tested the CMT on six healthy volunteers and six type 1 diabetic patients for 24 h in our clinical setting. Comparisons were made to HemoCue analyzer (Angelholm, Sweden) capillary blood glucose measurements (healthy volunteers) and to venous blood glucose concentration determined with a Hitachi analyzer (diabetic patients). The mean absolute relative error of the CMT glucose values from the blood glucose values was 17.8+/-15.5% (n = 167) for the healthy volunteers and 11.0+/-10.8% (n = 425) for the diabetic patients. The mean difference was 0.42+/-1.06 mM (healthy volunteers) and -0.17+/-1.22 mM (diabetic patients). Error grid analysis for the values obtained in diabetic patients demonstrated that 99% of CMT glucose values were within clinically acceptable regions (regions A and B of the Clarke Error Grid). The study results show that the CMT is an accurate technique for continuous online glucose monitoring.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/152091501300209615 | DOI Listing |
Alzheimers Dement
December 2024
Neurology Department Infanta Leonor Hospital, Madrid, Spain.
Background: biomarkers are essential in order to make a diagnosis with a high level of accuracy in patients with cognitive and behavior complaints. However, molecular imaging biomarkers not always provide an answer in daily clinical practice.
Methods: retrospective and descriptive study in patients with Amyloid PET (APscans) implemented according to rational use of this technic, between January 2019-November 2023 in Neurology Department, Infanta Leonor Hospital, Madrid, Spain.
Background: Apolipoprotein ε4 allele (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) with females having higher risk than males. Compared with non-carriers, cognitively normal, middle-aged APOE4 carriers have lower cerebral blood flow (CBF) decades before clinical symptoms appear. Early intervention to protect CBF would be critical for APOE4 carriers to mitigate AD progression.
View Article and Find Full Text PDFBackground: Type 2 diabetes mellitus (T2DM) is among the modifiable risk factors for Alzheimer's disease (AD) and ranks among the leading chronic diseases globally. It is characterized by elevated blood glucose levels and insulin resistance, which over time may impair memory performance. More so, saliva appears to be a promising biomarker for the diagnosis of AD since conventional methods appear invasive and expensive in the country.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Kansas Medical Center, Kansas City, KS, USA.
Background: Cerebral blood flow (CBF) and glucose utilization have both proven sensitive biomarkers of brain function in Alzheimer's disease. However, while blood flow supplies glucose to cells to meet local demand, and therefore, are inter-related, the two aspects are physiologically distinct. Our goal was to conduct a region-to-region correlation of magnetic resonance imaging (MRI) and F-fluorodeoxyglucose positron emission tomography (FDG-PET) biomarkers of cerebral blood flow and glucose utilization to determine whether these physiologically distinct biomarkers yield functionally distinct information.
View Article and Find Full Text PDFBackground: Apolipoprotein ε4 allele (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). Compared with non-carriers, cognitively normal APOE4 individuals have shown brain atrophy and lower cerebral blood flow (CBF) decades before AD pathological and clinical symptoms appear. The goal of the study is to determine if using Sirolimus, an FDA-approved mTOR inhibitor, could restore the brain volumes in structures related to cognitive functions and global CBF (gCBF) for asymptomatic APOE4 carriers compared with non-carriers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!